Tesamorelin ���景与作用机制 — Evidence Review

By Editorial Desk · published 2025-10-17 · last reviewed 2025-11-23 · Guide

GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-11-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

tesamorelin 背景与作用机制

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。

Tesamorelin Background and Mechanism

A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.

Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.

Tesamorelin at a glance

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Related pages on this site

• Measured playbook
• Measured playbook
• Tracked update
• Technical collection
• Quality handbook
• Reliable workbook
• Gradual update
• Durable briefing

Identity and Development Background

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Background and Clinical Profile

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Molecular Background and Receptor Mechanism

Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.

Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.

Background from the literature

Rennet () is a complex set of enzymes produced in the stomachs of ruminant mammals. Its key component is chymosin, a protease enzyme that curdles the casein proteins in milk. Rennet also contains other enzymes such as pepsin and a lipase. Rennet has traditionally been used to separate milk into solid curds and liquid whey, used in the production of cheeses. Rennet from calves has become less common for this use, to the point that less than 5% of cheese in the United States is made using animal rennet today. Most cheese is now made using chymosin derived from bacterial sources.

=== 1991 state attorney general race === In 1991, Kennedy ran for Louisiana attorney general to succeed the retiring William J. Guste. At 39, he was the youngest candidate in the race. In the state's jungle primary he received 288,382 votes (20%), placing third behind Ben Bagert, who received 313,143 (22%), and Richard Ieyoub, who received 447,457 (31%).

== Education == Tack received his Bachelor of Arts degree in physical chemistry from Princeton University in 1961 and his PhD from the University of California, Berkeley in 1965 for spectroscopic studies of photosynthesis.

=== Singles === "Ace Is in the House" with Tone Loc (1994) "Cuban Pete" (1995) – AUS No. 88, UK No. 31 "Somebody to Love" (1996) – AUS No. 62 "Cold Dead Hand" (2013) (as Lonesome Earl and the Clutterbusters)

== History == α-MSH was first isolated in the 1950s and its primary structure determined. By the 1960s, its role in promoting melanin diffusion was understood. In the 1980s, the University of Arizona synthesised more potent analogs of a-MSH, including afamelanotide. Afamelanotide was initially named melano-tan (or melanotan-I) due to its ability to tan skin with minimal sun exposure. Later, melanotan-II was synthesised. Following initial development at the University of Arizona as a sunless tanning agent, the Australian company Clinuvel conducted further clinical trials in that and other indications, and brought the drug to market in the European Union, the United States, and Australia. To pursue the tanning agent, melanotan-I was licensed by Competitive Technologies, a technology transfer company operating on behalf of University of Arizona, to an Australian startup called Epitan, which changed its name to Clinuvel in 2006. Early clinical trials showed that the peptide had to be injected about ten times a day due to its short half-life, so the company collaborated with Southern Research in the US to develop a depot formulation that would be injected under the skin, and release the peptide slowly. This was done by 2004. Multiple studies on the clinical effects of afamelanotide were conducted. According to ClinicalTrials.gov, Clinuvel sponsored several trials between 2007 and 2011 to explore its effects on erythropoietic protoporphyria, vitiligo, polymorphous light eruption, solar urticaria and acne vulgaris.

Sources: en.wikipedia.org

Reference notes

invagination The infolding of a membrane toward the interior of a cell or organelle, or of a sheet of cells toward the interior of a developing embryo, tissue, or organ, forming a distinct membrane-lined pocket. In the case of individual cells, the invaginated pocket may proceed to separate from the source membrane entirely, creating a membrane-bound vesicle within the cell, as in endocytosis.

Moreover, the typical secondary structure prediction methods do not account for the influence of tertiary structure on formation of secondary structure; for example, a sequence predicted as a likely helix may still be able to adopt a beta-strand conformation if it is located within a beta-sheet region of the protein and its side chains pack well with their neighbors. Dramatic conformational changes related to the protein's function or environment can also alter local secondary structure.

Bryant Park was initially supposed to reopen in late 1990 or early 1991. The reopening date was pushed back due to delays caused by the construction of the library's stacks. In June 1991, the city and BPRC reached an agreement to reopen the western section of Bryant Park on summer weekdays. The park was soft reopened on April 21, 1992, with the official reopening set for nearly a month later. The new design received widespread acclaim. Deemed "a triumph for many" by New York Times architectural critic Paul Goldberger, the renovation was lauded not only for its architectural excellence, but also for adhering to Whyte's vision. According to Goldberger, Biederman "understood that the problem of Bryant Park was its perception as an enclosure cut off from the city; he knew that, paradoxically, people feel safer when not cut off from the city, and that they feel safer in the kind of public space they think they have some control over." The renovation was lauded as "The Best Example of Urban Renewal" by New York magazine, and was described by Time as a "small miracle". Many awards followed, including a Design Merit Award from Landscape Architecture Magazine, and the 1996 Award for Excellence from the Urban Land Institute (ULI). The park has been extolled for its relative calmness and cleanness. Through the 21st century, Bryant Park remained a model of civic renewal that mayors of other cities, such as Jorge Elorza of Providence, Rhode Island, sometimes held up as a model to emulate. Bryant Park was described in the media as an example of New York City's 1990s revival.

Normal human hemoglobins are tetrameric proteins composed of two pairs of globin chains, each of which contains one alpha-like (α) globin and one beta-like (β) globin. Each globin chain is associated with an iron-containing heme moiety. Throughout life, the synthesis of the α and the β chains is balanced so that their ratio is relatively constant and there is no excess of either type. The specific α and β chains that are incorporated into Hb are highly regulated during development:

Sources: en.wikipedia.org

Reference notes

=== 1972: establishment === The National Gallery of Victoria Art School, founded in 1867 to teach fine art, was the VCA's foundation school. The Victorian College of the Arts was established in 1972 by a government order under the Victorian Institute of Colleges Act 1955, initiated by the Premier of Victoria and Minister for the Arts, Rupert Hamer. Subsequently, in 1973 the VCA was affiliated as a college of advanced education with the Victorian Institute of Colleges. The School of Music was established in 1974, the School of Drama in 1976 and the School of Dance in 1978.

== Genomics == Hydra has more than 20,000 genes, along with a set of six actinoporin-like toxin genes found in its nematocysts. An ortholog comparison analysis done in 2013 demonstrated that Hydra share a minimum of 6,071 genes with humans. Hydra is becoming an increasingly better model system as more genetic approaches become available. Transgenic hydra have become attractive model organisms to study the evolution of immunity. A draft of the genome of Hydra magnipapillata was reported in 2010. The genus Hydra is divided into two clades, the green hydras (e.g. H. viridissima) and the brown hydras (e.g. H. oligactis, H. vulgaris). The genomes of cnidarians are usually less than 500 Mb (megabases) in size, as in the green hydras, which has a genome size of approximately 300 Mb. In contrast, the genomes of brown hydras are approximately 1 Gb in size. This is because the brown hydra genome is the result of an expansion event involving LINEs, a type of transposable elements, in particular, a single family of the CR1 class. This expansion is unique to this subgroup of the genus Hydra and is absent in the green hydra, which has a repeating landscape similar to other cnidarians. These genome characteristics make Hydra attractive for studies of transposon-driven speciations and genome expansions. Due to the simplicity of their life cycle when compared to other hydrozoans, Hydras have lost many genes that correspond to cell types or metabolic pathways of which the ancestral function is still unknown.

In chemical systems, a system of atoms or molecules involving a change in chemical bond can be in a metastable state, which lasts for a relatively long period of time. Molecular vibrations and thermal motion make chemical species at the energetic equivalent of the top of a round hill very short-lived. Metastable states that persist for many seconds (or years) are found in energetic valleys which are not the lowest possible valley (point 1 in illustration). A common type of metastability is isomerism. The stability or metastability of a given chemical system depends on its environment, particularly temperature and pressure. The difference between producing a stable vs. metastable entity can have important consequences. For instances, having the wrong crystal polymorph can result in failure of a drug while in storage between manufacture and administration. The map of which state is the most stable as a function of pressure, temperature and/or composition is known as a phase diagram. In regions where a particular state is not the most stable, it may still be metastable. Reaction intermediates are relatively short-lived, and are usually thermodynamically unstable rather than metastable. The IUPAC recommends referring to these as transient rather than metastable. Metastability is also used to refer to specific situations in mass spectrometry and spectrochemistry.

Sources: en.wikipedia.org

Frequently asked questions